



## NEWS UPDATE

Date: 16/04/2026

### **Alembic Pharma Gets USFDA Nod for Generic Cancer & Arthritis Injection**



Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its generic Methotrexate injection, used in the treatment of various cancers and autoimmune conditions like rheumatoid arthritis. The approval covers multiple dosage forms, including 50 mg/2 ml multi-dose vials and 1g/40 ml single-dose vials, and confirms the drug is therapeutically equivalent to the reference product by Hospira. Methotrexate is widely prescribed for cancers such as leukemia, breast cancer, and osteosarcoma, as well as conditions like severe psoriasis and arthritis. This approval strengthens Alembic's oncology and specialty portfolio and enhances its presence in the US generics market, one of the largest pharmaceutical markets globally.

**Source:**

<https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-generic-cancer-arthritis-injection/articleshow/130300734.cms>